In vitro comparison of the adsorption of inflammatory mediators by blood purification devices

Benjamin Malard, Corine Lambert, John A Kellum, Benjamin Malard, Corine Lambert, John A Kellum

Abstract

Background: Septic shock, a leading cause of acute kidney injury, induces release of pro-/anti-inflammatory mediators, leading to increased mortality and poor renal recovery. This is the first in vitro study directly comparing three single-use blood purification devices in terms of removing sepsis-associated mediators and endotoxins.

Methods: In vitro hemoperfusion was performed using oXiris®, CytoSorb®, and Toraymyxin®. Heparinized human plasma from healthy volunteers was pre-incubated with pathologic quantities of inflammatory mediators and filtered in a closed-loop circulation model for 2 h. For each device, the removal of 27 inflammatory mediators was measured over time. Endotoxin removal mediated by oXiris and Toraymyxin was assessed using hemoperfusion over 6 h.

Results: Endotoxin (lipopolysaccharide) removal was most rapid with Toraymyxin; mean adsorptive clearance over the first 30 min was ~ 20 ml/min vs ~ 8 ml/min with oXiris (p < 0.05). There was minimal endotoxin removal with CytoSorb (1 ml/min). At 120 min, there was no significant difference between the endotoxin removal rates using oXiris (mean ± standard deviation, 68.0 ± 4.4%) and Toraymyxin (83.4 ± 3.8%); both were significantly higher vs CytoSorb (- 6.3 ± 4.9%; p < 0.05). Total removal with oXiris was 6.9 μg vs 9.7 μg for Toraymyxin, where the total lipopolysaccharide quantity introduced was approximately 15.8 μg. Removal rates of pro-/anti-inflammatory cytokines and other inflammatory mediators were similar between oXiris and CytoSorb and were higher with CytoSorb and oXiris vs Toraymyxin. Granulocyte colony-stimulating factor was only effectively adsorbed by CytoSorb (99.4%). Differences were detected between the adsorption mechanism of the devices; binding to oXiris was mainly ionic, while CytoSorb was hydrophobic. No specific protein adsorption was found qualitatively with Toraymyxin.

Conclusions: Adsorption rate kinetics varied for individual inflammatory mediators using the three blood purification devices. Mechanisms of adsorption differed between the devices. oXiris was the only device tested that showed both endotoxin and cytokine removal. oXiris showed similar endotoxin adsorption to Toraymyxin and similar adsorption to CytoSorb for the removal of other inflammatory mediators. Differences in device removal capacities could enable treatment to be more tailored to patients.

Keywords: Adsorption; Blood purification; Cytokines; Endotoxins; Removal rate; Septic shock; oXiris.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Competing interests

BM and CL are Baxter employees. JAK has a consulting contract with Baxter.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Centers of activity in the inflammatory network driving sepsis. Abbreviations: C5a complement 5a, HMGB-1 high-mobility group box 1 protein, IL-17A interleukin-17A, MIF macrophage migration inhibitory factor, TLR4 Toll-like receptor 4 [6]
Fig. 2
Fig. 2
LPS removal with oXiris, Toraymyxin, and CytoSorb. a LPS removal rate at t120 min. b LPS mean adsorption clearance over 30 min. Abbreviations: LPS lipopolysaccharide, N.S. not significant
Fig. 3
Fig. 3
LPS adsorption isotherm obtained with oXiris and Toraymyxin blood purification devices. Abbreviation: LPS lipopolysaccharide
Fig. 4
Fig. 4
Mean adsorption clearances over 30 min for the inflammatory mediators included in the study. Abbreviations: C3a complement 3a, C5a complement 5a, FGF fibroblast growth factor, G-CSF granulocyte-colony stimulating factor, HMGB-1 high-mobility group box 1 protein, IFN interferon, IL interleukin, IP interferon-induced protein, MCP monocyte chemoattractant protein, MIF macrophage migration inhibitory factor, MIP macrophage inflammatory protein, PAI plasminogen activator inhibitor, TNF tumor necrosis factor, Ra receptor agonist, α alpha, β beta, γ gamma
Fig. 5
Fig. 5
Electrophoretic patterns of membrane elutes. Upper panel is a Tris-glycine gel; lower panel is a Tris-tricine gel

References

    1. Quinto BM, Iizuka IJ, Monte JC, Santos BF, Pereira V, Durão MS, Dalboni MA, Cendoroglo M, OF S, Batista MC. TNF-α depuration is a predictor of mortality in critically ill patients under continuous veno-venous hemodiafiltration treatment. Cytokine. 2015;71:255–260. doi: 10.1016/j.cyto.2014.10.024.
    1. Zarbock A, Gomez H, Kellum JA. Sepsis-induced AKI revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care. 2014;20:588–595. doi: 10.1097/MCC.0000000000000153.
    1. Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol. 2011;22:999–1006. doi: 10.1681/ASN.2010050484.
    1. Kellum JA, Pike F, Yealy DM, Huang DT, Shapiro NI, Angus DC. Relationship between alternative resuscitation strategies, host response and injury biomarkers, and outcome in septic shock: analysis of the protocol-based care for early septic shock study. Crit Care Med. 2017;45:438–445. doi: 10.1097/CCM.0000000000002206.
    1. Esteban E, Ferrer R, Alsina L, Artigas A. Immunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge. Mediat Inflamm. 2013;2013:507539. doi: 10.1155/2013/507539.
    1. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776–787. doi: 10.1038/nri2402.
    1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–851. doi: 10.1056/NEJMra1208623.
    1. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. 2004;4:133–142. doi: 10.1038/nri1269.
    1. Baxter (2017) oXiris. Instructions for Use
    1. Toray Industries (2016) Toraymyxin PMX 20-R. Instructions for Use
    1. CytoSorbents Inc. (2012) CytoSorb 300mL device. Instructions for Use
    1. Patiha HE, Hidayat Y, Firdaus M. The langmuir isotherm adsorption equation: the monolayer approach. IOP Conf Ser: Mater Sci Eng. 2016;107:012067. doi: 10.1088/1757-899X/107/1/012067.
    1. Romaschin AD, Obiezu-Forster CV, Shoji H, Klein DJ. Novel insights into the direct removal of endotoxin by polymyxin B hemoperfusion. Blood Purif. 2017;44:193–197. doi: 10.1159/000475982.
    1. Harm S, Falkenhagen D, Hartmann J. Endotoxin adsorbents in extracorporeal blood purification: do they fulfill expectations? Int J Artif Organs. 2014;37:222–232. doi: 10.5301/ijao.5000304.
    1. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47. doi: 10.1186/cc5780.
    1. Cutuli SL, Artigas A, Fumagalli R, Monti G, Ranieri VM, Ronco C, Antonelli M, The EUPHAS 2 Collaborative Group Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care. 2016;6:77. doi: 10.1186/s13613-016-0178-9.
    1. Yaroustovsky M, Abramyan M, Krotenko N, Popov D, Plyushch M, Popok Z. Endotoxin adsorption using polymyxin B immobilized fiber cartridges in severe sepsis patients following cardiac surgery. Int J Artif Organs. 2014;37:299–307. doi: 10.5301/ijao.5000322.
    1. Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, Mimoz O, Coudroy R, Ferrandière M, Kipnis E, Vela C, Chevallier S, Mallat J, Robert R, The ABDOMIX Group Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41:975–984. doi: 10.1007/s00134-015-3751-z.
    1. Hattori N, Oda S. Cytokine-adsorbing hemofilter: old but new modality for septic acute kidney injury. Ren Replace Ther. 2016;2:41. doi: 10.1186/s41100-016-0051-1.
    1. Broman M (2017) Comparing cytokines, toxins adsorbing oXiris filter to ST150 filter during CRRT in patients with septic shock (oXiris). . Accessed 1 Nov 2017
    1. Shum HP, Chan KC, Kwan MC, Yan WW. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gram-negative bacterial infection. Hong Kong Med J. 2013;19:491–497.
    1. Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, Boer W, Verfaillie L, Spapen HD. Newly designed CRRT membranes for Sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013;59:99–106. doi: 10.1097/MAT.0b013e3182816a75.
    1. Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med. 2004;32:801–805. doi: 10.1097/01.CCM.0000114997.39857.69.
    1. Nakae H, Endo S, Inada K, Takakuwa T, Kasai T, Yoshida M. Serum complement levels and severity of sepsis. Res Commun Chem Pathol Pharmacol. 1994;84:189–195.
    1. Turani F, Busatti S, Martini S, Barchetta R, Belli A, Falco M. Tromboelastography (TEG) may detect hypercoagulation in early sepsis and improves anticoagulation during extracorporeal treatments. Crit Care. 2015;19(Suppl 1):P341. doi: 10.1186/cc14421.
    1. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15. doi: 10.1186/cc8872.
    1. Vesentini S, Soncini M, Zaupa A, Silvestri V, Fiore GB, Redaelli A. Multi-scale analysis of the Toraymyxin adsoprtion cartridge. Part I: molecular interaction of polymyxin B with endotoxins. Int J Artif Organs. 2006;29:239–250. doi: 10.1177/039139880602900210.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner